Back to NewsPublished: 19 Feb 2026Download AppJoin TelegramWhy Zydus’s New USFDA PAH Drug Could Turbocharge Your Portfolio#Zydus Lifesciences#USFDA Approval#Pulmonary Arterial Hypertension#Pharma Stocks#InvestingDownload AppJoin CommunityShare Article